As­traZeneca al­lo­cates £650M to boost its UK man­u­fac­tur­ing, cam­pus foot­print 

As­traZeneca is look­ing to spend £450 mil­lion ($827.1 mil­lion) to ex­pand its UK vac­cine man­u­fac­tur­ing site, on top of a £200 bud­get ($254.4 mil­lion) on a new fa­cil­i­ty to in­crease its pres­ence with­in the life sci­ences clus­ter in Cam­bridge, UK.

The vac­cine man­u­fac­tur­ing site in Speke, which is a 30-minute dri­ve from the cen­ter of Liv­er­pool, would boost the com­pa­ny’s R&D and man­u­fac­tur­ing ca­pa­bil­i­ties, ac­cord­ing to a press re­lease by the UK gov­ern­ment as a part of chan­cel­lor Je­re­my Hunt’s spring bud­get. The fa­cil­i­ty al­ready pro­duces child­hood vac­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER